Benegrastim for treating chemotherapy-induced neutropenia in women with breast cancer


featured image

Benegrastim is being developed for the treatment of neutropenia in patients receiving chemotherapy treatment for breast cancer.

Interventions: Benegrastim
Indications: Breast cancer
Therapeutic Areas: Breast Cancer , Immunology , Toxicology
Year: 2022

Benegrastim is being developed for the treatment of neutropenia in patients receiving chemotherapy treatment for breast cancer. Neutropenia occurs when an individual has low levels of neutrophils (a type of white blood cell), and it is a common side effect of cancer chemotherapy. Neutropenia can leave patients vulnerable to infections and cause complications such as febrile neutropenia (when neutropenia is accompanied by fever due to an infection) or neutropenic sepsis, which is potentially life-threatening. A common symptom of neutropenic sepsis is fever, and other signs include chills, fast heartbeat or breathing, cold or clammy skin, confusion, slurred speech, diarrhoea, and sickness. There are currently limited available treatments for chemotherapy-induced neutropenia and some of these require daily administration, which can be less convenient for patients.